Shares of Argenx SE surged to a record $954.50 on Thursday, extending gains that have pushed the Belgian biotechnology company’s market capitalization to new highs.
The stock’s latest milestone came as the broader healthcare sector continued to attract strong investor demand, driven by sustained interest in high-growth biotech firms. Argenx, which specializes in autoimmune disease treatments, has benefited from a favorable pipeline outlook and consistent clinical progress in its key drug candidates.
The company’s valuation has climbed steadily over the past year, reflecting optimism around its commercial strategy and expanding revenue streams. Argenx’s flagship therapy, Vyvgart, has gained traction in the U.S. and European markets, contributing to its financial performance.
Analysts have cited the stock’s momentum as a reflection of the broader trend in biotech, where investors remain willing to pay premium valuations for companies with promising drug pipelines and strong commercial execution. The company’s latest milestone comes amid a broader rally in the healthcare sector, which has outpaced the broader market in recent months.
No additional corporate actions or news events were cited as the driver for Thursday’s surge, suggesting the move was primarily market-driven. The stock’s trading volume remained elevated, indicating heightened investor interest.
